ArriVent BioPharma (AVBP) risk factors
Item 1A of every ArriVent BioPharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors83 risks14 new6 dropped14 reworded
ArriVent BioPharma faces critical geographic and supplier dependencies in China for its lead product candidate firmonertinib. Intellectual property and licensing agreements heavily dictate commercial success and financial obligations. Regulatory pricing pressures and cybersecurity threats present growing operational hurdles.
Filed Mar 05, 2026 - FY2024 10-K risk factors75 risks
ArriVent BioPharma is a clinical-stage company heavily reliant on firmonertinib and its exclusive license from Allist. The business faces significant capital requirements, clinical trial risks, and regulatory hurdles including potential accelerated approval paths. Operations are concentrated around 52 full-time employees relying on third-party manufacturers and clinical sites.
Filed Mar 03, 2025